We now know that cancer is a genetic disease, and that accumulation of molecular alterations in the genome is the basis of cancer initiation and progression. In the past ten years, the availability of the human genome sequence and progress and DNA sequencing has dramatically improved the knowledge and treatment of cancer. Personalized cancer testing and treatment are unique and personalized to each patient.
We are now able to measure circulating cancer cells in your blood. A count of circulating tumor cells present in the bloodstream is indicative of tumor burden and tumor spread. These tumor DNA cells can predict remission and prognosis and are valuable to assess the aggressiveness of your tumor. Evaluation of the cells allows for the early detection and diagnosis of new cancers as well as the monitoring of existing Cancers.
The cancer genome atlas research network has provided new insights into the personalized genomics mutations that drive disease progression in glioblastoma multiforme. Use targeted specific agents based on your cancer genetic mutations. Low-dose chemotherapy, natural substances, and cancer vaccines to penetrate your blood-brain barrier.Learn More
World wide breast cancer is the most frequently diagnosed cancer and the leading cause of death among females. Measure your new molecular and genomics predictive factors in your blood to determine personalized treatment programs. Targeted Low-dose chemotherapy, natural substances, and immunotherapy with checkpoint inhibitors and cancer vaccines New revolutionary treatmentsLearn More
Measure your genomic “driver mutations” and block these critical pathways using targeted low-dose targeted chemotherapy, natural substances, and immunotherapy with checkpoint inhibitors and cancer vaccines. Revolutionary new Combination therapy works best.Learn More
It is anticipated that in the future kidney cancer will soon become a chronic disorder as we understand the cancer genome. Learn about new personalized programs based on the testing of your cancer genome. Learn about immunotherapy with checkpoint inhibitors and cancer vaccines giving durable remissions To make kidney cancer become a chronic disease extending your lifeLearn More
Lung cancer is the leading cause of cancer-related deaths in the United States. Non-small cell lung cancer represents 80%, and small cell lung cancer represents 20%. Learn about new genomic tools for identification, prediction treatment, and prognosis. Personalized programs Using targeted low-dose chemotherapy, natural substances and immunotherapy with a checkpoint inhibitor and cancer vaccines New science-based revolutionary treatmentsLearn More
For Hodgkin lymphoma and non-Hodgkin’s lymphoma, new testing allows us to target cancer mutations using low-dose chemotherapy, natural substances, and immunotherapy with checkpoint inhibitors and cancer vaccines. Learn about new targeted, personalized revolutionary treatment programs.Learn More
The genetic and molecular understanding of melanoma is transforming its treatment. Measure your molecular mutational drivers making cancer more aggressive, which can be targeted and blocked. New low dose targeted chemotherapy, natural substances and immunotherapy with checkpoint inhibitors and cancer vaccines are extending patient’s lifeLearn More
Gynecological cancer research is changing the way we treat ovarian cancer. We can now measure the molecular pathways and block these “driver mutations using targeted revolutionary personalized treatments. These include targeted low-dose chemotherapy, natural substances, and immunotherapy, which checkpoint inhibitors and cancer vaccines. Do revolutionary personalize programsLearn More
We can now offer patients promising new therapies based on the new revolutionary genome at testing. By evaluating your cancer biomarkers, “we can now formulate personalized therapies utilizing low-dose targeted chemotherapy, natural substances, and immunotherapy with checkpoint inhibitors and cancer vaccines. Combining modern technology with our scientific knowledge and molecular diagnostics can give you better outcomes with this new revolutionary treatmentLearn More
Endometrial cancer is the most common gynecologic malignancy. With new genomic biomarkers, we can develop personalized programs, including low-dose chemotherapy, natural substances, and immunotherapy with checkpoint inhibitors and cancer vaccines. You cutting edge treatments from around the worldLearn More
Please call us for an in-depth discussion of your cancer and the treatment modalities from around the world available hereLearn More
The evaluation of disease-specific “molecular biomarkers” has revolutionized cancer care around the world. Those that occur early and at high frequency in tumors tend to be “driver mutations” whose function is vital for cancer cell proliferation and survival. These genes originate from the dysregulation of genes and are associated with the growth of cancer. One example is mutations in the epithelial growth factor receptor (EGFR). If the patient has an abnormality in this genetic pathway, it can be blocked using targeted therapies. We measure 72 different genes and pathways and for resistance factors.
It provides the best information about how each patient will respond to a specific chemotherapy agent and which is most effective. Low dose targeted chemotherapy, Chemotherapy resistance, and cancer metastasis are of critical importance. Testing for tumor mutational burden and microsatellite instability will ascertain the effectiveness of new immunotherapy with checkpoint inhibitors.
Natural substances testing
There are over 3000 plant species with anticancer activity. These have shown to block “molecular biomarkers pathways” that lead to cancer aggressiveness and metastasis. These are synergistic and nontoxic utilized in each patient.
Immune function testing
Evaluation and optimization of each patient’s immune function with cancer are of critical importance. Optimization for the administration and immunotherapy with cancer vaccines, which include autologous tumor vaccine, dendritic cell vaccine, and supportive oligonucleotide (SOT) and checkpoint inhibitors, is essential.
After extensive evaluation, a unique personalized program formulated for each patient. It includes low-dose targeted chemotherapy, natural substances, and immunotherapy with checkpoint inhibitors, autologous whole cancer vaccines, dendritic cell vaccine, and supportive oligonucleotide (SOT).
For more information on personalized cancer treatments, please call us at 480-361-7020.